China Regenerative Medicine International Limited
(Stock Code: 8158.HK)

THE WORLD'S FIRST BIO-ENGINEERED CORNEA “ACORNEA” FORMALLY INCORPORATING INTO CIVIC THE MEDICAL-CARE SYSTEM IN MAINLAND CHINA

(5 July, 2018 - Hong Kong) China Regenerative Medicine International Limited (the “Company”, stock code:8158.HK, together with its subsidiaries, the “Group”) is pleased to announce that the Changchun Social Medical Insurance Administration Authority of China has formally announced that cornea transplantation disease, including constructed cornea, under the serious sickness subsidy administration scope of low deductible diseases, thereby resolving the problems of overburdened personal medical expenses for certain patients. Such pilot medical insurance reformation on cornea transplantation signifies the fact that the world’s first bio-engineered cornea “Acornea”, researched and developed by the Group, will be formally incorporated into the civic social medical insurance system in Mainland China.

As the world’s first bioengineered cornea, “Acornea” successfully obtained the medical device registration certificate issued by The China Food and Drug Administration (CFDA) in 2015. Since launching to the commercial market, “Acornea” established a series of Chinese bioengineered corneal clinical application standards and industry norms, and trained more than 500 ophthalmologists nationwide in China. More than 100 hospitals nationwide used nationwide” for surgery. The number of operations exceeded 1000 units that achieved stable and good therapeutic effects.

According to the notice on the incorporation of Cornea Transplantation into Low Deductible Diseases (the “Notice”) issued by the Changchun Social Medical Insurance Administration Authority in June 2018, the Changchun Medical Care Bureau, under price-bargaining medical reform principles, conducted clinical price bargaining and group purchase negotiations with relevant hospitals in respect of cornea transplantation charges, including constructed cornea (such as bio-engineered cornea), and incorporated cornea transplantation into the serious sickness subsidy administration scope of low deductible diseases, thereby practically resolving the problems of overburdened personal medical expenses for certain patients, and enabling patients to recover their eyesight, and return to society.
The first batch of pilot medical institutions involved with cornea transplantation low deductible diseases are set out in the Notice, including five (5) hospitals: First Bethune Hospital of Jilin University, No. 2 Hospital of Jilin University, Sino-Japanese Union Hospital of Jilin University, Jilin Province People’s Hospital and Changchun Yinuo Ophthalmic Hospital.

The Notice also indicates that assigned medical institutions in other cities can apply to join the scheme as and when policies are running in a stable manner, and additional conditions are mature.

The Group deeply believes that following the facilitation of pioneer piloting policies in Jilin, other provinces nationwide will also, in future, launch relevant policies one after another to widely incorporate bio-engineered cornea into the civic medical insurance system, which will allow for preferential policies to be provided to more cornea disease patients, and thereby resolving social problems stemming from poverty caused by blindness.

(The End)